Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

A study reveals DNA and RNA epigenetics work together as a complementary system for precise gene regulation, crucial for cell ...

Researchers have identified various distinctive immune cells in cow's milk, creating potential avenues for enhancing animal ...

A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of the allergens responsible for eosinophilic esophagitis (EoE), an ...

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate ...

We live in a golden age for space exploration. Scientists are gathering massive amounts of new information and scientific ...

Scientists rebuild the body's own proteins and fats into nano delivery vans that get genetic medicines to exactly the right ...

In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...